Back to Search Start Over

[ 18 F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes.

Authors :
Santillo AF
Leuzy A
Honer M
Landqvist Waldö M
Tideman P
Harper L
Ohlsson T
Moes S
Giannini L
Jögi J
Groot C
Ossenkoppele R
Strandberg O
van Swieten J
Smith R
Hansson O
Source :
European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2023 Apr; Vol. 50 (5), pp. 1371-1383. Date of Electronic Publication: 2022 Dec 14.
Publication Year :
2023

Abstract

Purpose: To examine [ <superscript>18</superscript> F]RO948 retention in FTD, sampling the underlying protein pathology heterogeneity.<br />Methods: A total of 61 individuals with FTD (n = 35), matched cases of AD (n = 13) and Aβ-negative cognitively unimpaired individuals (n = 13) underwent [ <superscript>18</superscript> F]RO948PET and MRI. FTD included 21 behavioral variant FTD (bvFTD) cases, 11 symptomatic C9orf72 mutation carriers, one patient with non-genetic bvFTD-ALS, one individual with bvFTD due to a GRN mutation, and one due to a MAPT mutation (R406W). Tracer retention was examined using a region-of-interest and voxel-wise approaches. Two individuals (bvFTD due to C9orf72) underwent postmortem neuropathological examination. Tracer binding was additionally assessed in vitro using [ <superscript>3</superscript> H]RO948 autoradiography in six separate cases.<br />Results: [ <superscript>18</superscript> F]RO948 retention across ROIs was clearly lower than in AD and comparable to that in Aβ-negative cognitively unimpaired individuals. Only minor loci of tracer retention were seen in bvFTD; these did not overlap with the observed cortical atrophy in the cases, the expected pattern of atrophy, nor the expected or verified protein pathology distribution. Autoradiography analyses showed no specific [ <superscript>3</superscript> H]RO948 binding. The R406W MAPT mutation carriers were clear exceptions with AD-like retention levels and specific in-vitro binding.<br />Conclusion: [ <superscript>18</superscript> F]RO948 uptake is not significantly increased in the majority of FTD patients, with a clear exception being specific MAPT mutations.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1619-7089
Volume :
50
Issue :
5
Database :
MEDLINE
Journal :
European journal of nuclear medicine and molecular imaging
Publication Type :
Academic Journal
Accession number :
36513817
Full Text :
https://doi.org/10.1007/s00259-022-06065-4